Homology Medicines Inc (DELISTED) (FIXX:DL)
0.9347
-15.76
(-94.40%)
USD |
NASDAQ |
Mar 25, 16:00
0.92
-0.01
(-1.57%)
After-Hours: 20:00
Homology Medicines Research and Development Expense (Annual): 62.00M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 62.00M |
| December 31, 2022 | 98.35M |
| December 31, 2021 | 93.08M |
| December 31, 2020 | 100.39M |
| Date | Value |
|---|---|
| December 31, 2019 | 89.40M |
| December 31, 2018 | 47.95M |
| December 31, 2017 | 21.38M |
| December 31, 2016 | 5.695M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
62.00M
Minimum
2023
100.39M
Maximum
2020
88.65M
Average
93.08M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Societal CDMO Inc (DELISTED) | -- |
| AgeX Therapeutics Inc (DELISTED) | 1.025M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |